Q&A: How argenx’s CEO plans to create a sequel to Vyvgart (and beat the IRA)

Ryan Cross

Senior Science Correspondent

Tim Van Hauwermeiren is one of Europe’s most successful biotech entrepreneurs, having turned a €1 million investment crisis into a drug company worth more than …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Q&A: How argenx’s CEO plans to create a sequel to Vyvgart (and beat the IRA)

Ryan Cross

Senior Science Correspondent

Sign up to read this article for free.

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

Patient dies in Neurogene's Rett syndrome study

Are programs with compounded GLP-1s safe for your population?

Q&A: How ar­genx’s CEO plans to cre­ate a se­quel to Vyv­gart (and beat the IRA)

Ryan Cross

Senior Science Correspondent

Sign up to read this article for free.

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Q&A: How argenx’s CEO plans to create a sequel to Vyvgart (and beat the IRA)

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

Patient dies in Neurogene's Rett syndrome study

Are programs with compounded GLP-1s safe for your population?